Download Citation
Article Source:
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
Hanson A,
Elpek K,
Duong E,
Shallberg L,
Fan M,
et al.
(2020)
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
PLOS ONE 15(9): e0239595.
https://doi.org/10.1371/journal.pone.0239595